Celecoxib (100 and 200 mg cap): Supply issue and new look

Supply issue New look Active

The funded brand of celecoxib is changing due to supply issues with the current brand.

3 November 2022

Supply status: Further Celebrex stock expected in November. Final shipment of Celecoxib Pfizer expected early December.  

Affected products

The supplier has notified us of ongoing supply challenges impacting the Celecoxib Pfizer capsules. Currently, there is a supply issue affecting both the 100 mg and 200 mg capsules.

  • Chemical: Celecoxib
  • Presentations: Cap 100 mg / Cap 200 mg 
  • Brand: Celecoxib Pfizer
  • Pharmacode: 2521164 / 2521172
  • Subsidy: $3.45 / $3.20
  • Measure / Qty: per 60 / per 30

Schedule listing for celecoxib(external link)

Replacement product listed

We brought forward the listing of Celebrex to 1 August 2022 (100 mg Pharmacode 2642433 | 200 mg Pharmacode 2642441).

Schedule listings for Celebrex(external link)

Supplies of Celebrex arrived in August and September. Another shipment is expected in November.

A final shipment of Celecoxib Pfizer is expected December 2022. 

Either brand may be available at your wholesaler.

We will update this notice once a decision to delist Celecoxib Pfizer is made. We will ensure there is time for existing stocks to be used up.

What's staying the same

Celebrex capsules look identical to and are the same as Celecoxib Pfizer capsules. The capsules have the same active ingredient and work in the body in the same way. They are both supplied by Aspen Pharmacare. 

The Celebrex brand products are approved by Medsafe. 

Who to contact

If you have any questions about the new look packaging, talk with your doctor, nurse or pharmacist.

Pharmacies can contact their wholesalers for enquiries about stock availability.

If you have any other questions about this issue, email enquiry@pharmac.govt.nz

Pharmacists, please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.